Valuation: Indivior

Market Cap 490.74Cr 430.87Cr 396.59Cr 369.56Cr 696.96Cr 47TCr 711.13Cr 4.77TCr 1.85TCr 23TCr 1.84TCr 1.8TCr 80TCr P/E 2026 *
12.7x
P/E 2027 * 11.1x
Enterprise Value 496.19Cr 435.65Cr 401Cr 373.66Cr 704.7Cr 47TCr 719.02Cr 4.82TCr 1.87TCr 23TCr 1.86TCr 1.82TCr 81TCr EV / Sales 2026 *
3.94x
EV / Sales 2027 * 3.44x
Free-Float
94.38%
Yield 2026 *
-
Yield 2027 * -
Change 5-day change 1-year change 3-year change Capi.($)
+0.09%+1.57% - - 490.74Cr
-0.64%+6.67%+53.59%+154.11% 1,06300Cr
+0.00%+5.39%+62.89%+53.44% 61TCr
-0.23%+6.88%+32.14%+86.34% 44TCr
+1.29%-0.96%+26.12%+20.22% 32TCr
+1.38%+0.13%+35.51%+35.72% 29TCr
+0.29%-0.40%+27.50%+41.74% 28TCr
-1.05%+1.82%-27.20%-40.62% 22TCr
-0.22%+2.82%+24.37%+62.75% 20TCr
-0.29%+0.65%+12.75%+63.45% 16TCr
Average +0.09%+2.83%+27.52%+53.02% 39.79TCr
Weighted average by Cap. +0.08%+4.16%+38.22%+77.25%

Financials

2026 *2027 *
Net sales 125.79Cr 110.44Cr 101.66Cr 95Cr 178.65Cr 12TCr 182.28Cr 1.22TCr 473.74Cr 5.87TCr 472.3Cr 462.09Cr 20TCr 130.78Cr 114.83Cr 105.69Cr 98Cr 185.74Cr 12TCr 189.52Cr 1.27TCr 492.55Cr 6.1TCr 491.05Cr 480.44Cr 21TCr
Net income 41Cr 36Cr 33Cr 31Cr 59Cr 3.94TCr 60Cr 402.87Cr 156.09Cr 1.93TCr 155.62Cr 152.25Cr 6.73TCr 47Cr 42Cr 38Cr 36Cr 67Cr 4.5TCr 69Cr 459.64Cr 178.09Cr 2.21TCr 177.55Cr 173.71Cr 7.68TCr
Net Debt 5.45Cr 4.79Cr 4.4Cr 4.1Cr 7.74Cr 518.15Cr 7.9Cr 53Cr 21Cr 254.34Cr 20Cr 20Cr 885.16Cr -40Cr -35Cr -33Cr -30Cr -57Cr -3.84TCr -58Cr -392.11Cr -151.92Cr -1.88TCr -151.46Cr -148.19Cr -6.55TCr
Logo Indivior
Indivior Pharmaceuticals, Inc. is a global pharmaceutical company engaged in developing medicines to treat substance-use disorders (SUD). The Company provides treatment for addiction, including SUBLOCADE (buprenorphine extended-release) injection for subcutaneous use, a long-acting injectable (LAI) for opioid use disorder and OPVEE (Nalmefene) nasal spray for opioid overdose recovery. Its core products include SUBOXONE Film, SUBOXONE Tablet, SUBUTEX Tablet, OPVEE (nalmefene), and SUBLOCADE. SUBOXONE Film is a buprenorphine and naloxone sublingual film. SUBOXONE Tablet is a buprenorphine and naloxone sublingual tablet. SUBUTEX Tablet is a buprenorphine sublingual tablet. SUBOXONE Film, SUBOXONE Tablet, SUBUTEX Tablet, and SUBLOCADE are treatments for opioid use disorder (OUD). In addition to its commercially available products, its product pipeline includes two drug candidates for the treatment of OUD. It sells its products in the United States and in other selected areas of the world.
Employees
-
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-